Masimo Corp Stock Price, News & Analysis

Masimo (NASDAQ: MASI) has launched the full market release of its Hydration Index (Hi™), integrated within the Masimo W1™ watch. This advanced health-tracking wearable offers continuous pulse oximetry and hydration level monitoring, crucial for athletes and health-conscious individuals. The technology builds on Masimo's expertise in pulse oximetry, enabling users to assess hydration and physiological status in real-time. Notably, the product has not received FDA clearance for medical use in the U.S.

Masimo (NASDAQ: MASI) announced a controlled trial published in the Journal of the College of Physicians and Surgeons Pakistan, showing the benefits of its SpHb® hemoglobin monitoring technology in major surgeries. The study found that patients monitored with SpHb had significantly lower postoperative red blood cell transfusion rates (median 0 IUs for SpHb group versus 2 IUs for control; p=0.020) and higher hemoglobin levels in ICU (8.41 g/dL vs. 7.75 g/dL; p=0.033). Researchers emphasized that SpHb can enhance patient blood management, potentially reducing mortality and morbidity.

Masimo (NASDAQ: MASI) will present at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 8:30 a.m. ET. A live webcast of the presentation will be accessible on Masimo's website, with a replay available afterward. Masimo is a leader in medical technology, focusing on innovative monitoring solutions that enhance patient outcomes and lower care costs. Their SET pulse oximetry technology, utilized globally, has proven effective in critical applications for neonatal care and surgical monitoring.

The United States District Court for the Central District of California has ruled in favor of Masimo (NASDAQ: MASI), determining that former engineer Marcelo Lamego misappropriated trade secrets related to Masimo’s pulse oximetry technology. The court ordered Lamego to abandon patent applications and return confidential information. Furthermore, the sale of Lamego's True Wearables pulse oximeter is permanently enjoined due to the misuse of Masimo's trade secrets. Masimo has another pending lawsuit against Apple scheduled for trial in March 2023, alleging further misappropriation of trade secrets.

Masimo (NASDAQ: MASI) will participate in the Stifel 2022 Healthcare Conference on November 15, 2022, at 1:50 p.m. Eastern Time. A live webcast will be available on their website, with a replay following the presentation. Masimo specializes in innovative medical monitoring technologies, including noninvasive pulse oximetry and continuous monitoring tools, aiming to improve patient outcomes while reducing healthcare costs. Their products are utilized in over 100 million patients globally, establishing their presence in leading hospitals worldwide.

Masimo (NASDAQ: MASI) reported a strong performance for Q3 2022, with consolidated revenue reaching $549.3 million, up 78.7% from $307.4 million in Q3 2021. Healthcare revenue was $327.2 million, reflecting 6.4% growth, while non-healthcare revenue stood at $222.1 million. GAAP net income was $37.9 million ($0.70 per diluted share), with non-GAAP net income at $53.9 million ($1.00 per diluted share). For Q4 2022, Masimo updated its guidance to $581 million to $611 million in revenue.

Masimo (NASDAQ: MASI) will announce its third quarter 2022 financial results on November 8, 2022, after market close. A conference call hosted by CEO Joe Kiani and CFO Micah Young will occur at 1:30 p.m. PT (4:30 p.m. ET) to discuss these results. This event is crucial for investors as Masimo's innovative medical technologies aim to improve patient outcomes and reduce care costs. Interested participants can register for the call to receive necessary details. More information about Masimo and its products is available on its website.

Masimo (NASDAQ: MASI) has issued a statement responding to a lawsuit filed by Politan Capital Management in Delaware. The company claims the lawsuit follows Politan's failed attempts to gain a board seat for its founder, Quentin Koffey, who lacks relevant industry experience. Masimo's board emphasizes the adoption of bylaw amendments to enhance transparency for shareholders and reject Politan's demands as self-serving. The legal team includes prestigious law firms like Quinn Emanuel Urquhart & Sullivan LLP.

Politan Capital Management, holding 8.8% of Masimo (NASDAQ: MASI), has filed a lawsuit against the company following recent bylaws amendments. These amendments, implemented on September 9, 2022, effectively hinder stockholders' rights to nominate directors, requiring sensitive information that is often confidential. The lawsuit seeks to declare the amendments unenforceable and challenges the directors' fiduciary duties. Quentin Koffey of Politan stated that Masimo's defensive measures, including a poison pill and a staggered board, leave them no option but to pursue legal action to preserve stockholder rights.